Aggravation of immunoglobulin a nephropathy by hyperuricemia: A mini-review on current findings and new concepts

Iranian Journal of Kidney Diseases

Volumn 8, Issue 5, 2014, Pages 359-362

  Nasri, Hamid ^a   Baradaran, Azar ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Allopurinol; Chronic kidney disease; Ig A nephropathy; Uric acid

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; URIC ACID;

BLOOD; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; GLOMERULONEPHRITIS, IGA; HUMAN; HYPERURICEMIA; KIDNEY; KIDNEY FAILURE, CHRONIC; RISK FACTOR; TREATMENT OUTCOME;

ALLOPURINOL; DISEASE PROGRESSION; GLOMERULONEPHRITIS, IGA; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; KIDNEY; KIDNEY FAILURE, CHRONIC; RISK FACTORS; TREATMENT OUTCOME; URIC ACID;

EID: 84906847172     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Lv J, Shi S, Xu D, et al. Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62:891-9.
2. Nasri H, Mortazavi M, Ghorbani A, et al. Oxford-MEST classification in IgA nephropathy patients: A report from Iran. J Nephropathol. 2012;1:31-42.
3. Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012;59:865-73.
4. Baradaran A. Renal vascular lesions in IgA nephropathy. J Renal Inj Prev. 2013;2:37-8.
5. Barratt J, Feehally J. Primary IgA nephropathy: new insights into pathogenesis. Semin Nephrol. 2011;31:349-60.
6. Nasri H. IgG deposition in IgA nephropathy patients. J Renal Inj Prev. 2012;2:11-3.
7. Nasri H, Ardalan MR. Association between the proportion of globally sclerotic glomeruli and various morphologic variables and clinical data of IgA nephropathy patients. J Renal Inj Prev. 2012;1:27-30.
8. Mubarak M. Significance of immunohistochemical findings in Oxford classification of IgA nephropathy: The need for more validation studies. J Nephropathol. 2013;2:210-3.
9. Baradaran A. IgG deposition in IgA nephropathy patients. J Renal Inj Prev. 2013;2:39-40.
10. Mubarak M. Oxford classification of IgA nephropathy: Broadening the scope of the classification. J Nephropathol. 2012;1:13-6.
11. Torbati PM. Globally sclerotic glomeruli in IgA nephropathy patients. J Renal Inj Prev. 2012;1:7-8.
12. Nasri H, Sajjadieh S, Mardani S, et al. Correlation of immunostaining findings with demographic data and variables of Oxford classification in IgA nephropathy. J Nephropathol. 2013;2:190-5.
13. Baradaran A. Comment on: Association between the proportion of globally sclerotic glomeruli and various morphologic variables and clinical data of IgA nephropathy patients. J Renal Inj Prev. 2012;1:9-10.
14. Ohno I. Relationship between hyperuricemia and chronic kidney disease. Nucleosides Nucleotides Nucleic Acids. 2011;30:1039-44.
15. Momeni A. Serum uric acid and diabetic nephropathy. J Renal Inj Prev. 2012;1:37-8.
16. Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27:1479-85.
17. Nasri H, Ardalan MR. Significance of hyperuricemia in immunoglobulin A nephropathy. J Renal Inj Prev. 2013;2:105-6.
18. Cheng GY, Liu DW, Zhang N, Tang L, Zhao ZZ, Liu ZS. Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up. Clin Nephrol. 2013;80:40-6.
19. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystalindependent mechanism. Hypertension. 2001;38:1101-6.
20. Tonelli M, Riella M. Chronic kidney disease and the aging population. Iran J Kidney Dis. 2014;8:87-92.
21. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991;266:8604-8.
22. Ardalan MR, Sanadgol H, Nasri H, Baradaran A, Tamadon MR, Rafieian-Kopaei R. Impact of vitamin D on the immune system in kidney disease. J Parathyr Dis. 2013;1:17-20.
23. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol. 2001;281:F1-11.
24. Tamadon MR, Ardalan MR, Nasri H. World Kidney Day 2013; acute renal injury; a global health warning. J Parathyr Dis. 2013;1:27-8.
25. Sulikowska B, Manitius J, Odrowaz-Sypniewska G, Lysiak-Szydlowska W, Rutkowski B. Uric acid excretion and dopamine-induced glomerular filtration response in patients with IgA glomerulonephritis. Am J Nephrol. 2008;28:391-6.
26. Cui MJ, Zhang BH, Xiao QF, Zhu FL, Wang HY. [The relationship between hyperuricaemia and clinic pathology of IgA nephropathy]. Zhonghua Nei Ke Za Zhi. 2011;50:659-63. Chinese.
27. Kovács T, Vas T, Kovesdy CP, et al. Metabolic syndrome and other cardiovascular risk factors associated with the progression of IgA nephropathy. Clin Kidney J. 2013; 6:395-401.
28. Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35:153-60.
29. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-9.
30. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388-93.
31. Mubarak M, Nasri H. Significance of segmental glomerulosclerosis in IgA nephropathy: What is the evidence? J Renal Inj Prev. 2013;2:113-5.
32. Nasri H, Mubarak M. Significance of vasculopathy in IgA nephropathy patients with regard to Oxford classification and immunostaining findings: a single center experience. J Renal Inj Prev. 2013;2:41-45.
33. Perlstein TS, Gumieniak O, Hopkins PN, et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int. 2004;66:1465-70.
34. Mubarak M, Nasri H. What nephrolopathologists need to know about antiphospholipid syndrome-associated nephropathy: Is it time for formulating a classification for renal morphologic lesions? J Nephropathol. 2014;3:4-8.
35. Nasri H, Rafieian-Kopaei M. Hyperuricemia; a new look at an old problem. J Nephropharmacol. 2012;1:13-4.
36. Amiri M, Nasri H. Secondary Hyperparathyroidism in chronic kidney disease patients; current knowledge. J Parathyr Dis. 2014;2:1-2.
37. Rafieian-Kopaei M, Behradmanesh S, Kheiri S, Nasri H. Association of serum uric Acid with level of blood pressure in type 2 diabetic patients. Iran J Kidney Dis. 2014;8:152-4.